Terns Capex To Revenue vs Ev To Sales Analysis

TERN Stock

USD 6.78 0.39 5.44%

Terns Pharmaceuticals financial indicator trend analysis is much more than just breaking down Terns Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Terns Pharmaceuticals is a good investment. Please check the relationship between Terns Pharmaceuticals Capex To Revenue and its Ev To Sales accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

Capex To Revenue vs Ev To Sales

Capex To Revenue vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Terns Pharmaceuticals Capex To Revenue account and Ev To Sales. At this time, the significance of the direction appears to have totally related.

The correlation between Terns Pharmaceuticals' Capex To Revenue and Ev To Sales is 1.0. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Terns Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Terns Pharmaceuticals' Capex To Revenue and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Terns Pharmaceuticals are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Capex To Revenue i.e., Terns Pharmaceuticals' Capex To Revenue and Ev To Sales go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from Terns Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Terns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.At this time, Terns Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 14th of November 2024, Selling General Administrative is likely to grow to about 41 M, while Issuance Of Capital Stock is likely to drop about 39.5 M.

	2021	2022	2023	2024 (projected)
Interest Income	170K	2.1M	12.9M	13.5M
Net Interest Income	170K	2.1M	12.9M	13.5M

Interest Income Net Interest Income

Terns Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.66	0.38	1.0	0.75	0.9	0.69	-0.57	-0.82	0.71	0.56	0.47	-0.86	-0.87	1.0	0.76	0.86	-0.76	0.77	0.88	-0.72	0.92	0.88	1.0	-0.78	1.0
Other Current Liab	0.66		0.92	0.64	0.94	0.58	0.88	-0.01	-0.87	0.69	0.07	0.78	-0.58	-0.61	0.62	0.64	0.7	-0.93	0.7	0.71	-0.2	0.57	0.84	0.66	-0.33	0.6
Total Current Liabilities	0.38	0.92		0.35	0.75	0.27	0.7	0.09	-0.63	0.39	0.01	0.65	-0.43	-0.44	0.33	0.41	0.41	-0.81	0.46	0.44	0.14	0.26	0.57	0.38	0.04	0.3
Total Stockholder Equity	1.0	0.64	0.35		0.74	0.9	0.69	-0.56	-0.81	0.71	0.56	0.46	-0.86	-0.87	1.0	0.75	0.86	-0.75	0.76	0.88	-0.74	0.93	0.88	1.0	-0.79	1.0
Other Liab	0.75	0.94	0.75	0.74		0.71	0.93	0.02	-0.92	0.86	0.01	0.83	-0.58	-0.61	0.73	0.69	0.81	-0.92	0.74	0.78	-0.44	0.71	0.95	0.75	-0.56	0.71
Net Tangible Assets	0.9	0.58	0.27	0.9	0.71		0.63	-0.39	-0.89	0.8	0.35	0.46	-0.81	-0.84	0.9	0.74	0.98	-0.73	0.92	0.96	-0.82	0.99	0.84	0.9	-0.92	0.9
Property Plant And Equipment Net	0.69	0.88	0.7	0.69	0.93	0.63		-0.11	-0.83	0.7	0.15	0.95	-0.51	-0.52	0.67	0.47	0.72	-0.86	0.64	0.74	-0.4	0.66	0.92	0.69	-0.5	0.65
Net Debt	-0.57	-0.01	0.09	-0.56	0.02	-0.39	-0.11		0.12	0.15	-0.99	0.09	0.59	0.56	-0.58	-0.17	-0.24	0.13	-0.2	-0.36	0.34	-0.44	-0.21	-0.57	0.27	-0.59
Retained Earnings	-0.82	-0.87	-0.63	-0.81	-0.92	-0.89	-0.83	0.12		-0.88	-0.12	-0.72	0.7	0.75	-0.8	-0.79	-0.96	0.9	-0.94	-0.95	0.55	-0.87	-0.92	-0.81	0.72	-0.79
Accounts Payable	0.71	0.69	0.39	0.71	0.86	0.8	0.7	0.15	-0.88		-0.18	0.62	-0.5	-0.54	0.71	0.77	0.87	-0.73	0.8	0.79	-0.65	0.78	0.86	0.71	-0.8	0.7
Cash	0.56	0.07	0.01	0.56	0.01	0.35	0.15	-0.99	-0.12	-0.18		-0.06	-0.59	-0.56	0.57	0.16	0.21	-0.17	0.18	0.34	-0.27	0.4	0.22	0.56	-0.2	0.58
Non Current Assets Total	0.47	0.78	0.65	0.46	0.83	0.46	0.95	0.09	-0.72	0.62	-0.06		-0.23	-0.25	0.44	0.33	0.57	-0.71	0.53	0.6	-0.22	0.48	0.79	0.46	-0.36	0.42
Non Currrent Assets Other	-0.86	-0.58	-0.43	-0.86	-0.58	-0.81	-0.51	0.59	0.7	-0.5	-0.59	-0.23		1.0	-0.86	-0.55	-0.78	0.78	-0.68	-0.76	0.68	-0.83	-0.7	-0.86	0.64	-0.85
Other Assets	-0.87	-0.61	-0.44	-0.87	-0.61	-0.84	-0.52	0.56	0.75	-0.54	-0.56	-0.25	1.0		-0.86	-0.6	-0.82	0.79	-0.73	-0.8	0.67	-0.85	-0.71	-0.87	0.66	-0.86
Cash And Short Term Investments	1.0	0.62	0.33	1.0	0.73	0.9	0.67	-0.58	-0.8	0.71	0.57	0.44	-0.86	-0.86		0.75	0.86	-0.73	0.76	0.88	-0.75	0.93	0.87	1.0	-0.8	1.0
Common Stock Shares Outstanding	0.76	0.64	0.41	0.75	0.69	0.74	0.47	-0.17	-0.79	0.77	0.16	0.33	-0.55	-0.6	0.75		0.77	-0.58	0.84	0.8	-0.37	0.71	0.67	0.76	-0.6	0.75
Short Term Investments	0.86	0.7	0.41	0.86	0.81	0.98	0.72	-0.24	-0.96	0.87	0.21	0.57	-0.78	-0.82	0.86	0.77		-0.81	0.95	0.97	-0.75	0.97	0.89	0.86	-0.88	0.85
Non Current Liabilities Total	-0.76	-0.93	-0.81	-0.75	-0.92	-0.73	-0.86	0.13	0.9	-0.73	-0.17	-0.71	0.78	0.79	-0.73	-0.58	-0.81		-0.73	-0.78	0.47	-0.73	-0.89	-0.76	0.52	-0.72
Other Current Assets	0.77	0.7	0.46	0.76	0.74	0.92	0.64	-0.2	-0.94	0.8	0.18	0.53	-0.68	-0.73	0.76	0.84	0.95	-0.73		0.97	-0.54	0.88	0.77	0.77	-0.75	0.75
Other Stockholder Equity	0.88	0.71	0.44	0.88	0.78	0.96	0.74	-0.36	-0.95	0.79	0.34	0.6	-0.76	-0.8	0.88	0.8	0.97	-0.78	0.97		-0.65	0.95	0.87	0.88	-0.82	0.87
Total Liab	-0.72	-0.2	0.14	-0.74	-0.44	-0.82	-0.4	0.34	0.55	-0.65	-0.27	-0.22	0.68	0.67	-0.75	-0.37	-0.75	0.47	-0.54	-0.65		-0.85	-0.65	-0.72	0.94	-0.75
Net Invested Capital	0.92	0.57	0.26	0.93	0.71	0.99	0.66	-0.44	-0.87	0.78	0.4	0.48	-0.83	-0.85	0.93	0.71	0.97	-0.73	0.88	0.95	-0.85		0.86	0.92	-0.93	0.93
Property Plant And Equipment Gross	0.88	0.84	0.57	0.88	0.95	0.84	0.92	-0.21	-0.92	0.86	0.22	0.79	-0.7	-0.71	0.87	0.67	0.89	-0.89	0.77	0.87	-0.65	0.86		0.88	-0.74	0.86
Total Current Assets	1.0	0.66	0.38	1.0	0.75	0.9	0.69	-0.57	-0.81	0.71	0.56	0.46	-0.86	-0.87	1.0	0.76	0.86	-0.76	0.77	0.88	-0.72	0.92	0.88		-0.78	1.0
Capital Stock	-0.78	-0.33	0.04	-0.79	-0.56	-0.92	-0.5	0.27	0.72	-0.8	-0.2	-0.36	0.64	0.66	-0.8	-0.6	-0.88	0.52	-0.75	-0.82	0.94	-0.93	-0.74	-0.78		-0.8
Net Working Capital	1.0	0.6	0.3	1.0	0.71	0.9	0.65	-0.59	-0.79	0.7	0.58	0.42	-0.85	-0.86	1.0	0.75	0.85	-0.72	0.75	0.87	-0.75	0.93	0.86	1.0	-0.8

Click cells to compare fundamentals

Terns Pharmaceuticals Account Relationship Matchups

Terns Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.9M	92.3M	168.1M	287.0M	268.5M	170.3M
Other Current Liab	3.3M	8.2M	4.7M	6.2M	7.6M	5.8M
Total Current Liabilities	5.0M	22.8M	6.8M	8.5M	11.9M	10.5M
Total Stockholder Equity	4.2M	68.6M	160.3M	276.9M	255.4M	153.6M
Other Liab	630K	877K	947K	1.1M	1.2M	806.7K
Net Tangible Assets	(90.8M)	(117.4M)	172.2M	276.9M	318.5M	334.4M
Property Plant And Equipment Net	961K	1.2M	1.0M	1.8M	1.0M	1.2M
Net Debt	(12.3M)	(62.0M)	(47.7M)	(142.0M)	(79.3M)	(83.3M)
Retained Earnings	(91.9M)	(131.9M)	(182.1M)	(242.4M)	(332.6M)	(316.0M)
Accounts Payable	1.6M	935K	2.1M	1.6M	2.5M	1.8M
Cash	12.3M	74.9M	47.7M	143.2M	79.9M	80.8M
Non Current Assets Total	1.7M	1.4M	1.1M	1.8M	1.1M	1.4M
Non Currrent Assets Other	719K	246K	94K	37K	56K	53.2K
Other Assets	719K	246K	94K	37K	1.0	0.95
Cash And Short Term Investments	19.7M	74.9M	166.0M	283.1M	263.4M	163.9M
Common Stock Shares Outstanding	25.1M	25.1M	25.3M	36.0M	71.3M	37.9M
Short Term Investments	7.3M	0.0	118.3M	139.9M	183.5M	192.7M
Liabilities And Stockholders Equity	23.9M	92.3M	168.1M	287.0M	268.5M	170.3M
Non Current Liabilities Total	14.7M	877K	947K	1.6M	1.2M	1.1M
Other Current Assets	461K	331K	948K	2.1M	4.0M	4.2M
Other Stockholder Equity	1.2M	14.6M	174.6M	520.2M	588.0M	617.4M
Total Liab	19.7M	23.7M	7.8M	10.1M	13.2M	12.2M
Net Invested Capital	(90.8M)	(104.6M)	160.3M	276.9M	255.4M	268.1M
Property Plant And Equipment Gross	961K	1.2M	2.2M	3.2M	2.6M	1.9M
Total Current Assets	22.2M	90.9M	166.9M	285.2M	267.4M	168.9M
Accumulated Other Comprehensive Income	(106K)	(124K)	(338K)	(822K)	(19K)	(20.0K)
Net Working Capital	17.3M	68.0M	160.1M	276.7M	255.5M	158.4M
Property Plant Equipment	961K	1.2M	1.0M	757K	870.6K	924K

Pair Trading with Terns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Terns Stock

0.55	DRUG	Bright Minds Biosciences	Pair Corr
0.37	CDIOW	Cardio Diagnostics	Pair Corr

The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.

The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:

How To Invest In Terns

Details

Is Terns Stock a good investment?

Details

What is Terns Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.32)

Revenue Per Share

0.035

Return On Assets

(0.26)

Return On Equity

(0.39)

The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Terns Capex To Revenue vs Ev To Sales Analysis

Capex To Revenue vs Ev To Sales

Capex To Revenue vs Ev To Sales Correlation Analysis

Correlation Coefficient

Capex To Revenue

Ev To Sales

Terns Pharmaceuticals fundamental ratios Correlations

Terns Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Terns Pharmaceuticals fundamental ratios Accounts

Pair Trading with Terns Pharmaceuticals

Moving against Terns Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Cash	- 0.99	Net Debt
Short Term Investments	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Other Current Assets	- 0.94	Retained Earnings
Capital Stock	- 0.93	Net Invested Capital
Non Current Liabilities Total	- 0.93	Other Current Liab